Innocare Pharma Ltd. Class A · SSE:688428
Innocare Pharma Ltd. Class A — J.P. Morgan Healthcare Conference 2024
34 slides from Innocare Pharma Ltd. Class A's conference presentation, Feb 2, 2024
Slide 1: Pushing the Frontier of Healthcare Innovation
Pushing the Frontier of Healthcare Innovation - InnoCare Introduction February 2, 2024
Slide 2: Disclaimer
Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subs
Slide 3: Our Mission & Vision: Science Drives Innovation for the Benefit of Patients
Our Mission & Vison: Science Drives Innovation for the Benefit of Patients To Become a Global Biopharmaceutical Leader that Develops and Delivers Innovative Therapies for Patients Worldwide Oncology Autoimmune Our Therapeutic Focus 3
Slide 4: Exciting 8 Years Journey of Innovation and Development
Exciting 8 Years Journey of Innovation and Development 2.5 years IND cleared Hemato- r/r CLL/SLL, r/r MCL NDA r/r MZL NDA Project in CHN, AUS, oncology trial r/r MCL NDA approved in approved in Orelabrutinib initiation US initiated in CHN approved in CHN SGP CHN (BTK inhibitor) AID Solid tumor Serie
Slide 5: Highlights of InnoCare's Strength and Advantages
Highlights of InnoCare’s Strength and Advantages Fully-integrated & Well Positioned Fully-fledged A Leading Hemato- Efficient Drug Portfolio in Auto- Commercial & Healthy oncology Franchise Innovation Platform immune Diseases Financial Position Majority of assets come Comprehensive coverage Assets c
Slide 6: A Leading Hemato-oncology Franchise
A Leading Hemato- oncology Franchise - Orelabrutinib: Potential Best-in-Class BTKi - BCL-2 Inhibitor: 100% Efficacy with Combo Potential - Continuously Enriching Hemato-oncology Portfolio
Slide 7: Comprehensive Coverage in Hemato-oncology Indications & MOAs
Comprehensive Coverage in Hemato-oncology Indications & MOAs ICP-490 E3 Ligase Small molecule ICP-B02 ICP-B05 CD3 X CD20 CCR8 Biologics Biologics ICP-248 BCL-2 Small molecule Orelabrutinib ICP-490 BTK Tafasitimab ICP-248 Small molecule CD19 E3 Ligase BCL-2 Biologics Small molecule Small molecule MM
Slide 8: Orelabrutinib
Clinical Advantages 2024 NDA Submissions Significant BTK occupation: r/r MCL in USA ~100% at 50 mg QD and above 1L CLL/SLL in CHN Much improved safety profile r/r MZL in SGP No ≥ Grade 3 AF observed Once-daily dosing Marketed Indications Ongoing Clinical Trials Orelabrutinib r/r CLL/SLL, r/r MCL, r/
Slide 9: Orelabrutinib: Unique Structure Design Provides Much Improved Target Selectivity
Orelabrutinib: Unique Structure Design Provides Much Improved Target Selectivity Optimized Structure of Orelabrutinib Ibrutinib C481 binder H-bonding Acalabrutinib Eliminates Chiral C481 binder Center Hinge Region Less （Single Ring Core） H-Binding Eliminates Sites Chiral Center C481 binder Smaller A
Slide 10: Orelabrutinib: Outstanding Kinase Selectivity Among BTK Inhibitors
Orelabrutinib: Outstanding Kinase Selectivity Among BTK Inhibitors Orelabrutinib Ibrutinib Acalabrutinib Zanubrutinib Cleaner inhibitor (KINOME scan* at 1M) ➢ High inhibition potency: IC50 ~1.6 nM ➢ Outstanding selectivity profile in the class by KINOME scan (456 kinases) ➢ Clean of activity in Pan
Slide 11: Orelabrutinib: Potential Best-in-Class BTKi for B-cell Malignancies
Orelabrutinib: Potential Best-in-Class BTKi for B-cell Malignancies r/r CLL/SLL r/r MCL r/r MZL Safety in BCM 0.0% 93.8% 83.0% 58.9% ≥ Grade 3 atrial fibrillation Overall response rate Overall response rate Overall response rate (ORR) (ORR) (ORR) 6.0% Any grade diarrhea 30.0% 27.4 91.0% Complete res
Slide 12: ICP-248 (BCL-2i): Improved Molecular Design Provides Unique Merits
ICP-248 (BCL-2i): Improved Molecular Design Provides Unique Merits Soft-spot blocked in ICP-248 Advantages of ICP-248 Eliminated active metabolite Reduced DDI risks ABT-199 (Venetoclax) design M27, a major metabolite of ABT-199, accounts for 12% in human plasma Improved PK & efficacy Strong CYP2C8 a
Slide 13: ICP-248: Early Clinical Result Shows Outstanding Efficacy
ICP-248: Early Clinical Result Shows Outstanding Efficacy ORR: 6 out of 6 Significant Synergy with Orelabrutinib Vehicle, PO, QD Asset ICP-248 APG-25751 BGB-114172 Venetoclax3 Venetoclax4 ICP-248, 30 mg/kg, PO, QD Orelabrutinib, 1 mg/kg, PO, BID Orelabrutinib, 3 mg/kg, PO, BID ICP-248+Orelabrutinib,
Slide 14: Continuously Enriching Hemato-oncology Portfolio and Modalities
Continuously Enriching Hemato-oncology Portfolio and Modalities Tafasitimab* ICP-B02** ICP-B05** ICP-490 Approved in HK Potential BIC Potential FIC E3 ligase small molecule CD3 x CD20 BsAb anti-CCR8 mAb Eligible for urgent use in Bo’ao Targeted protein degrader and GBA CD20+B-cell Malignancies Immun
Slide 15: Well Positioned Portfolio in Autoimmune Diseases
Well Positioned Portfolio in Autoimmune Diseases - Orelabrutinib: Versatile BTKi in AID - TYK2/JAK1 Dual Inhibitor: Potential Best Efficacy for AD
Slide 16: Autoimmune Disease Strategy
Autoimmune Disease Strategy AD Ph II Positive Result T cell pathway Psoriasis Ph II On-going LN Under Evaluation ICP-332 (TYK2i-JH1) CD ICP-488 (TYK2i-JH2) UC SLE Global First, Ph IIa PoC Positive, Ph IIb On-going Global Ph II Positive Result B cell pathway MS Ph III Registration Trial On-going ITP
Slide 17: Enormous Unmet Medical Needs Exist in Autoimmune Diseases
Enormous Unmet Medical Needs Exist in Autoimmune Diseases Nephrology LN MN >150 autoimmune diseases identified Gastroenterology UC CD Dermatology >500 M patients world wide AD PSO CSU AA Hematology ITP AIHA AA >40 M patients in China Neurology MS NMO MoG-EN Rheumatology SLE PSA SS IgG4-RD InnoCare c
Slide 18: Orelabrutinib: Unlimited Potential in Autoimmune Diseases
Orelabrutinib: Unlimited Potential in Autoimmune Diseases Orelabrutinib Potential BIC profile Close to market Class leading progress First BTKi for SLE for MS BTKi for ITP in NMOSD • Best-in-Class • Ph III registrational • Globally first and • No BTK inhibitors approved for NMOSD yet efficacy trial
Slide 19: Orelabrutinib: Potential Best-in-Class BTKi for Multiple Sclerosis
Orelabrutinib: Potential Best-in-Class BTKi for Multiple Sclerosis Adjusted Mean Cumulative number of New Gd+ T1 Brain Dose CSF Conc. ~2h BTKi Company Lesions by Visit (N=115) (mg) (ng/mL) 8 Orelabrutinib InnoCare 150 QD 31.3 7 50mg QD dose for Placebo / patients on placebo Evobrutinib Merck KGaA 75
Slide 20: ICP-332, ICP-488: TYK2 Inhibitors with Different Selectivity Profiles
ICP-332, ICP-488: TYK2 Inhibitors with Different Selectivity Profiles Active site binding Allosteric site binding JH2 (pseudokinase domain) Blocking the ATP binding site Inactive state JH1 (kinase domain) IC50 (nM) IC50 (nM) @1 mM ATP Inhibitor TYK2 JH2 TYK2 JH1 JAK1 JAK2 JAK3 ICP-332 2319 0.5 19
Slide 21: ICP-332: Major TYK2 Plus Minor JAK1 Inhibition for Atopic Dermatitis
ICP-332: Major TYK2 Plus Minor JAK1 Inhibition Provides New Possibilities for Effective Treatment of Atopic Dermatitis (AD) Inhibition of TYK2/JAK1 Possesses Heavy Disease Burden Extensive Market Potential Potential Synergy Global AD Market1 USD B 18.5% 22.2 9.5 2023 2028E Source:1 Frost & Sullivan
Slide 22: ICP-332: Highly Significant Improvements in Main Efficacy Analyses
ICP-332: Highly Significant Improvements in Main Efficacy Analyses Percent Change from Percent Change from High Proportion of Patients Baseline in EASI Baseline in EASI Achieved Total Score at Week 4 - Main Analysis (FAS) Total Score by visit (FAS) EASI 50 and EASI 75 at Week 4 Placebo ICP-332 80mg
Slide 23: ICP-332: Potential Best Efficacy for AD
ICP-332: Potential Best Efficacy for AD Efficacy Comparison of ICP-332 EASI Comparison of ICP-332 and Monotherapy of Various Innovative Drugs and Upadacitinib at Week 41* ICP-332 80mg QD 4W Upadacitinib 15mg QD 4W ICP-332(TYK2/JAK1) ph2 80mg qd 4w 56.0% *Not a head-to-head comparison Updadacitinib(J
Slide 24: ICP-332: Quick Response in Improving Patient Quality of Life
ICP-332: Quick Response in Improving Patient Quality of Life Quick and Statistically Significant Improvement of Patient Quality of Life Response from Day 2 Dermatology Life Quality Index (DLQI) Score Pruritus Numerical Rating Scale (NRS) Change from Baseline by Visits (Full Analysis Set) p<0.01 Plac
Slide 25: ICP-332: Safety and Tolerability Profiles Similar to Placebo
ICP-332: Safety and Tolerability Profiles Similar to Placebo Overall Summary of Treatment-Related Adverse Events (TRAE) Placebo ICP-332 80 mg ICP-332 120 mg (N = 25) (N = 25) (N = 24) All TRAEs 9 (36.0%) 6 (24.0%) 10 (41.7%) Mild 8 (32.0%) 6 (24.0%) 8 (33.3%) Moderate 1 (4.0%) 0 2 (8.3%) Severe 0 0
Slide 26: Innovative Solid Tumor Assets
Innovative Solid Tumor Assets - New Drug Discovery and Combination
Slide 27: Solid Tumors Strategy
Solid Tumors Strategy Benefit patients more Provide the right medicine, to the right patient, at the right time ICP-723 ICP-192 NTRK/ FGFR ROS1 Precision Medicine RTKi EGFRi VEGFi KRASi RAFi Immuno- MEKi CDK4/6i PD-1/PD-L 1 ICI oncology / Combo ICP-189 ICP-B05 SHP-2 CCR8 Cornerstone of combination t
Slide 28: Keep Investing in Innovative Early Stage Assets for Solid Tumors
Keep Investing in Innovative Early Stage Assets for Solid Tumors CDK4/6 FGFR EGFR/ PD-1 SHP2 ALK KRAS PI3K/AKT /MEK/ ICP-B05 (anti-CCR8 mAb) /mTOR RAF ICP-189 ICP-B05 • SHP 2 inhibitor for NSCLC & others • Immuno-oncology target with Treg regulation • Ph I dose escalation in solid tumors (10-120 mg)
Slide 29: Robust Growth Outlook
Robust Growth Outlook - Robust Portfolio - Short-term Certainty and Visibility
Slide 30: Strong Growth Momentum Secured by Robust Portfolio and Global Collaboration
Strong Growth Momentum Secured by Robust Portfolio and Fueled by Global Innovation & Collaboration Benefit Millions of Patients World-wide Advancement of current clinical pipeline ICP-490 ICP-189 Orelabrutinib Orelabrutinib ICP-B02 r/r MCL in USA, MZL in SGP, etc. ITP, SLE, NMOSD in CHN ICP-B05 … Or
Slide 31: InnoCare 2024 Milestones and Catalysts
InnoCare 2024 Milestones and Catalysts 2024 H1 2024 H2 NDA submission for 1L CLL/SLL in CHN Orelabrutinib NDA submission for r/r MCL in the USA NDA submission for r/r MZL in SGP Tafasitamab NDA sub. in CHN for r/r DLBCL Hemato- Ph I preliminary data readout oncology ICP-248 USA IND filing & approval
Slide 32: Thank you for your attention
e®@ ey~S INNOCARE ee Thank you for your attention
Slide 33: Product Pipeline – Hemato-oncology
Product Pipeline – Hemato-oncology Dose Dose Expansion Pivotal Trial Escalation Expected Drug Target Indication(s) Rights IND Enabling Market PHIa PHIb PH2* PH2** PH3 NDA Filing r/r CLL/SLL CHN r/r MCL CHN,SG CHN r/r MZL ICP-022/ BTK 1L: CLL/SLL Orelabrutinib 2024 1L: MCL 1L: MCD DLBCL Hemato- Oncol
Slide 34: Product Pipeline – Solid Tumors and Autoimmune Diseases
Product Pipeline – Solid Tumors and Autoimmune Diseases Dose Escalation Dose expansion Pivotal Trial Drug Target Indication(s) Rights IND Enabling Filed Market PHIa PHIb PH2* PH2** PH3 SLE MS ICP-022/ BTK Orelabrutinib Auto- ITP immune NMOSD Disease ICP-332 TYK2 – JH1 Atopic Dermatitis Autoimmune IC
InnoCare Pharma — J.P. Morgan Healthcare Conference 2024 on 6ix